CONCARLO HOLDINGS, LLC

  • CONCARLO HOLDINGS, LLC

Developing solutions for drug-resistant breast cancer

MORE ABOUT US

About us

TECHNOLOGY

 

Breast cancer remains a significant burden on human health. Almost 250,000 US women will be diagnosed this year and approximately 40,000 women will die. ER/PR+ (endocrine responsive) Her2- tumors occur in approximately 90,000 breast cancer patients each year, of which 20,000 develop drug resistance. For these patients, despite advances in available drugs, the best existing solutions do not provide durable arrest of the tumors. The patient becomes resistant to the drug and overall survival rates are unchanged.

 

Using our patent technologies, we can dramatically increase drug efficacy and diagnostic evaluations for ER/PR+ Her 2- patients. IpY, a cdk inhibitor, specifically addresses drug resistance issues. Concarlo believes that, as a cdk inhibitor, IpY will have efficacy in many different cancers. ApY is an antibody that can be used to pinpoint patients who will respond to cdk4 inhibiting therapies. This built-in biomarker and surrogate endpoint should highlight tumors that would be responsive to this type of therapy, providing clinicians with needed information before treatment is started and as it is progressing.

 

Our Team

News

 

Going Through It Together

Stacy and Catherine’s Grand Canyon Hike




Save

Save


  • WRITE US AT

    info@concarlo.com


  • OUR LAB

    Downstate Biotechnology Incubator
    760 Parkside Avenue, Room 208
    Brooklyn, NY 11226

  • REACH US HERE

    917.856.9688



Contact Us